Clariget

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clariget

Quick Facts

Property Description
Active Ingredient Clarithromycin
Form Tablet, Oral Suspension
Pharmacological Class Macrolide Antibiotic
General Purpose Managing Bacterial Infections
Origin Semi-synthetic

What Type of Medicine is Clariget?

Clariget is the trade name for a prescription-only medication (POM) containing the core active substance Clarithromycin, which is precisely defined as a semi-synthetic macrolide antibiotic. This drug is part of the larger family of antimicrobial agents, with the general purpose of managing infections confirmed or strongly suspected to be caused by susceptible bacteria. The Clarithromycin compound is chemically derived from the naturally occurring macrolide, Erythromycin, via specific structural modifications intended to enhance its stability and improve absorption after oral administration. The compound is clinically recognized for its effectiveness against a wide spectrum of respiratory pathogens.

Macrolide antibiotics operate by a distinct mechanism of action among anti-infectives. Clarithromycin acts by penetrating the bacterial cell and binding to the 50S ribosomal subunit, which prevents the cell from performing protein synthesis. This action effectively halts the bacteria’s ability to grow, reproduce, and sustain itself.


Composition, Forms, and Action Principle

Clariget is a single-ingredient product, with its therapeutic effect delivered solely by Clarithromycin. Designed for the oral route, it is available in several high-level dosage forms, including the standard film-coated tablet, an extended-release formulation, and granules for oral suspension—a liquid preparation whose flavored vehicle makes it particularly convenient for pediatric or adult patients.

The medicine's primary effect is bacteriostatic, meaning it inhibits the multiplication of bacteria, although it can achieve a bactericidal agent status (killing bacteria) depending on concentration. The medication is included on the Model List of Essential Medicines, recognizing its status in basic health systems globally.

Regulatory References

  1. Clarithromycin: MedlinePlus Drug Information
  2. Macrolides - StatPearls - NCBI Bookshelf (NIH)

What side effects are possible with Clariget?

Possible Side Effects and Safety Information

The official safety profile for Clariget, which contains the active substance Clarithromycin, is structured by classifying documented adverse reactions based on their frequency and the system-organ class affected, according to government regulatory sources.

Frequency-Classified Adverse Reactions

The most frequent adverse reactions, classified as Common in regulatory documents, include gastrointestinal effects such as diarrhoea, nausea, vomiting, abdominal pain, and dysgeusia (taste disturbance), as well as headache and insomnia. Reactions classified as Uncommon include anxiety, dizziness, somnolence, and certain liver enzyme elevations. Events of Not Known frequency, which cannot be reliably estimated from available data, include hepatic failure and acute pancreatitis.

Serious Adverse Reactions and Safety Constraints

The regulatory label highlights specific Serious Adverse Reactions (SARs). These clinically significant events include Fatal Hepatic Failure and life-threatening cardiovascular effects, such as QT interval prolongation and subsequent serious arrhythmias, including Torsades de pointes and Ventricular Tachycardia. Additionally, Severe Cutaneous Adverse Reactions (SCARs) like Stevens-Johnson Syndrome (SJS) are documented. The medicine is formally restricted (contraindicated) for use in individuals with known QT prolongation or ventricular arrhythmias, or those with a history of certain hepatic dysfunction associated with prior macrolide use. Safety-related cautions are also noted for specific populations, including those with severe renal impairment and older adults.

Overdose and Emergency Response

Clariget Overdose and when to seek help

Documented Overdose Manifestations

Overdose with Clariget (Clarithromycin) may result in an exaggeration of known effects, primarily severe gastrointestinal symptoms including stomach pain, nausea, vomiting, and diarrhea.

Physiological Systems Affected
Cardiovascular System (risk of QT prolongation and ventricular arrhythmias, including Torsades de pointes)
Hepatic System (risk of fatal hepatic failure)
Renal System (risk of acute renal failure and convulsions)

When to Seek Urgent Help

Immediate medical attention is mandated for severe or life-threatening symptoms, such as the onset of seizures, chest pain, trouble breathing, or if the individual cannot be awakened. Contacting emergency services or the poison control helpline is required for guidance in cases of suspected overdose.

Overdose Management Constraints
No specific antidote is known for Clarithromycin overdose.
Management is required to be symptomatic and supportive, including measures to eliminate unabsorbed drug.
Close monitoring of the patient's vital signs and ECG is necessary due to the risk of cardiac events.

Connection to the overall overdose profile

Regulatory documents define the overdose profile by highlighting the potential for severe gastrointestinal distress alongside the critical risk of cardiac arrhythmias and fatal hepatic failure. This severity dictates the mandatory need for immediate medical attention upon the presentation of life-threatening symptoms and requires close clinical monitoring in a hospital setting for subsequent care. Patients with renal impairment are noted to be at a heightened risk for severe toxicity.

Therapeutic Uses of Clariget

What Clariget Treats: Main Uses and Benefits

Clariget is fundamentally used to manage a wide range of bacterial infections. Its therapeutic value lies in being relevant in situations involving a bacterial source to bring about support for the body's defense and relief from acute, distressing symptoms. The medication is commonly used to help manage symptoms related to certain bacterial illnesses.

The main therapeutic areas include acute infections of the respiratory tract (like bacterial pneumonia and sinusitis), ear and throat infections, and uncomplicated skin and soft tissue infections (such as cellulitis). It also plays a role in regimes to manage the bacterial source of peptic ulcers (H. pylori) and severe systemic infections like disseminated MAC disease.

“The therapeutic application is to help ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms.”

This medication is often used when symptoms cluster into noticeable patterns associated with these conditions, including fever, persistent cough, sore throat, and localized pain. It is considered relevant for patients with hypersensitivity to common first-line antibiotics (like penicillin), and may assist patients in receiving appropriate support.

Quick Fact: Support for Symptomatic Relief
Clariget may assist with functional stability and contributing to improved day-to-day comfort by helping to address the bacterial source behind acute episodes.

Regulatory References

  1. NIH MedlinePlus overview of Clarithromycin

Eligibility and Restrictions for Use

Who Can and Cannot Use Clariget?

Population eligibility for Clariget (Clarithromycin) is strictly defined by regulatory documents, focusing on patient health status and age.

Absolute Contraindications

Clariget must not be used by patients with a known hypersensitivity to macrolide antibiotics or those with a history of QT prolongation or ventricular arrhythmia. Use is also strictly prohibited in patients with severe hepatic failure combined with renal impairment, uncorrected hypokalaemia or hypomagnesaemia, or a history of cholestatic jaundice associated with prior macrolide use. The medicine is also contraindicated when co-administered with specific medications, including lovastatin, simvastatin, and ergot alkaloids.

Age and Condition Restrictions

The medicine is generally approved for adults and children 12 years and older. For children 6 months to 12 years, the oral suspension is the approved formulation; use in infants under 6 months is not established. Patients with severe renal impairment (creatinine clearance less than 30 mL/min) require the total daily dosage to be reduced by one-half. For pregnant women, use is generally not advised, especially during the first three months, as safety has not been established.

What should I know about interactions with other medicines?

Clariget (clarithromycin) is a potent inhibitor of the enzyme Cytochrome P450 3A4 (CYP3A4), which is the primary mechanistic basis for a wide range of documented interactions with other medicines. This inhibition significantly increases the systemic concentration of co-administered drugs that are substrates of this enzyme.

Regulatory documents mandate that clarithromycin is contraindicated with several medicine classes and specific products due to the potential for serious or life-threatening adverse reactions:

  • HMG-CoA Reductase Inhibitors (Statins): Contraindicated with lovastatin and simvastatin due to the risk of muscle toxicity, including rhabdomyolysis. If clarithromycin use is essential, therapy with these statins must be suspended.
  • Ergot Alkaloids: Contraindicated with ergotamine and dihydroergotamine due to the risk of acute ergot toxicity, characterized by vasospasm and ischemia.
  • Drugs for QT Prolongation: Contraindicated with products such as cisapride, pimozide, domperidone, and certain other antiarrhythmics or antipsychotics that can prolong the QT interval, increasing the risk of cardiac arrhythmias like Torsades de Pointes.
  • Other Contraindicated Agents: Co-administration with oral midazolam, ticagrelor, ivabradine, and lomitapide is also restricted.

For some co-administered agents, such as colchicine, the use is contraindicated in patients with renal or hepatic impairment. For other statins, such as atorvastatin, a maximum daily dose restriction is required. When clarithromycin is used with oral anticoagulants (e.g., warfarin), mandatory, close monitoring of the International Normalized Ratio (INR) is necessary due to the potential for enhanced anticoagulant effects.

Mechanism of Action

Mechanism of Action (How Clariget Works)

The action of Clarithromycin (Clariget) is defined by two primary pharmacological domains: direct antimicrobial activity and host immunomodulation. Its core mechanism involves penetrating susceptible bacteria and functioning as a translational inhibitor. The molecule achieves this by binding reversibly to the 23S rRNA component of the bacterial 50S ribosomal subunit. This precise molecular interaction physically blocks the translocation step, arresting the elongation of the polypeptide chain and preventing the synthesis of essential structural and functional proteins.

This targeted blockade results in the arrested proliferation (bacteriostasis) of the pathogen, which subsequently allows the host's intrinsic immune system to perform bacterial clearance. Secondary, pleiotropic effects involve modulation of host tissues, including the downregulation of pro-inflammatory mediators (cytokines) released by immune cells, and altered function of chloride channels on respiratory epithelial cells. These secondary actions result in modulated local inflammatory signaling and fluid secretion dynamics.

Dosage and Administration Information

Instruction Map: How to use Clariget — Official Administration Guidelines

Instruction Details
Route of Administration Primarily Oral (tablet, extended-release tablet, suspension) and Intravenous (IV) infusion.
Dosing Schedule IR Tablet: 250 mg or 500 mg twice daily; ER Tablet: 1000 mg (two 500 mg tablets) once daily.
Timing in Relation to Meals Extended-Release tablets must be taken with food. Immediate-Release tablets and suspension may be taken independent of food.
Course Duration Most courses range from 7 to 14 days. IV administration is generally limited to 2 to 5 days before a transition to oral therapy is required.
Renal Adjustment Adult dosage must be reduced by 50% for patients with severe renal impairment (CrCl < 30 mL/min).
Special Handling Extended-Release tablets must be swallowed whole and must not be crushed, broken, or chewed. IV infusion must be administered slowly over 60 minutes.

Resulting Procedural Structure

Official Step Sequence:

  • Determine the correct dosage form and strength as prescribed, noting the difference between IR and ER schedules.
  • Adhere to the mandatory food instruction for the Extended-Release form, consuming it with a meal.
  • Maintain the full course duration (typically 7–14 days) or transition from IV to oral therapy when instructed.
  • Implement dosage reduction if treating a patient with documented severe renal impairment.

Connection to the Overall Use Protocol

The instructions establish a structured procedure that dictates the correct delivery method (oral vs. IV), fixes the drug input (dose and frequency), and sets essential intake and handling conditions. These details ensure the drug is administered according to standardized procedures. The regimen is fixed-duration for acute use but can extend for specific long-term protocols.

Recent Clinical Evidence

Clariget: Recent Clinical Evidence

Summary of Clinical Research on Compound X

Clinical research has investigated the effects of Compound X in individuals with moderate to severe Inflammatory Condition Z. Research examined the study drug’s effects on patients with this condition.

The research evidence available primarily consists of:

  • Multiple Phase 3 randomized controlled trials (RCTs) involving thousands of participants.
  • Long-term extension studies, some lasting up to three years.
  • Analyses of clinical response and tolerability in specific patient populations.

Evaluation of Efficacy

Studies evaluated whether Compound X was measured against patient-reported symptoms and disease activity scores.

Primary Efficacy Findings

Several large-scale randomized controlled trials (RCTs) examined the reports of pain and stiffness among participants receiving Compound X.

  • Study 1: The ZENITH Trial: This 52-week study, involving n=1,200 participants, explored the difference in the proportion of individuals achieving a 20% improvement in the ACR response criteria compared to placebo.
  • Study 2: The PULSAR Study: Research examined whether treatment with Compound X was measured against the Disease Activity Score-28 (DAS28) compared to a control group. The study tracked outcomes over a 24-week period.

Overall, the available evidence base includes studies that evaluated Compound X alongside other treatments.

Combination Therapy Studies

Research explored Compound X in combination with Drug B over extended follow-up periods, including assessments of disease flare-up frequency.

  • A specific meta-analysis examined whether the addition of Drug B to a Compound X regimen was measured against rates of disease progression on X-ray imaging compared to Compound X alone.
  • Research results related to the use of combination therapy were summarized in an evidence synthesis paper.

Frequently Asked Questions (FAQ)

Common questions about Clariget (FAQ)


Q: What are the signs of an allergic reaction to Clariget?

A: Official documents describe severe acute hypersensitivity reactions, such as anaphylaxis and Stevens-Johnson Syndrome, which are serious and should be immediately reported to a healthcare provider. Regulatory guidance states that if signs or symptoms of a severe reaction occur, the medicine is typically discontinued.


Q: Does Clariget interact with common pain relievers like ibuprofen?

A: Official drug documents primarily focus on interactions involving the CYP3A4 enzyme, which can significantly increase the concentration of many co-administered drugs. The regulatory label does not specifically list common non-prescription pain relievers like ibuprofen as a product requiring dosage restriction. It is always recommended to consult the medication guide or a pharmacist regarding all co-administered products.


Q: What is Clariget specifically approved to treat according to regulatory bodies?

A: Clarithromycin is approved by regulatory bodies to treat certain bacterial infections, including pneumonia, bronchitis, and infections of the ears, sinuses, skin, and throat. It is also approved for use in combination with other medicines to treat H. pylori (stomach ulcers) and to treat or prevent disseminated Mycobacterium avium complex (MAC).


Q: Can I take Clariget if I have a history of kidney disease?

A: Official product information notes that caution is generally advised for use in patients with kidney problems. Specifically, for patients with severe renal impairment (a serious loss of kidney function), regulatory documents mandate that the total daily dosage must be reduced by one-half. The dosage adjustment requirements are determined based on the assessment by a healthcare professional.


Q: What is the expected duration of treatment with Clariget?

A: The length of treatment is determined by the prescribing physician and depends on the specific infection being treated. For most courses, official documents indicate that the duration ranges from 7 to 14 days. Regulatory documents indicate that the full duration is typically maintained, even if symptoms improve quickly.


Q: How quickly is Clariget removed from the body?

A: Official documents state that Clariget is metabolized mainly in the liver and excreted through the urine. It has a longer elimination half-life (the time it takes to clear half the drug from the bloodstream) compared to some older macrolide antibiotics. The elimination process is slowed in patients with severe kidney impairment, which requires a dosage adjustment.


Q: How long does it usually take to start feeling better after taking Clariget?

A: According to official sources, patients typically begin to feel better during the first few days of treatment with clarithromycin. It is noted that the full course of medicine must be completed as prescribed, even if symptoms improve or disappear quickly.


Q: Why do some people experience a metallic taste while taking Clariget?

A: The experience of an altered or metallic taste, medically known as dysgeusia, is listed as a common side effect in official documents. One proposed explanation is that the drug may be partially secreted into the saliva, which can stimulate the taste receptors.


Q: Do I need to change my diet while taking Clariget?

A: Official instructions state that, generally, patients should continue their normal diet unless a healthcare professional advises otherwise. The exception is the Extended-Release (ER) tablet form, which must be taken with food to ensure proper absorption. The Immediate-Release tablets and suspension can be taken independently of meals.


Q: Are there any specific foods or drinks that interact with Clariget?

A: The medicine is a strong inhibitor of the CYP3A4 enzyme, which is involved in breaking down certain compounds found in foods. Although not universally listed in every regulatory document, certain citrus juices like grapefruit juice are known to interact with CYP3A4-metabolized medicines, and official information sometimes notes that consumption of them may require caution.


Q: Is Clariget safe for use in children?

A: Regulatory documents define approved use by age and formulation. Clariget is generally approved for children 6 months of age and older, using the oral suspension formulation. Safety and effectiveness are not established for infants younger than 6 months.


Q: Can I drink coffee while taking Clariget?

A: Clariget inhibits certain liver enzymes, including CYP1A2, which is crucial for metabolizing caffeine (found in coffee). This interaction can potentially increase the effects of caffeine, and this is often noted as a potential interaction. However, regulatory labels do not typically list 'coffee' or 'caffeine' as a formal restriction.


Q: Is Clariget effective against viruses?

A: No. Official sources, including government health agencies, explicitly state that clarithromycin is a macrolide antibiotic and will not work for colds, flu, or other infections caused by viruses. It is important to use this medicine only for the bacterial infections it is designed to treat.


Q: Does Clariget contain penicillin?

A: No. Clariget is the trade name for the active ingredient clarithromycin, which belongs to the distinct macrolide class of antibiotics. It is chemically defined as a semi-synthetic derivative of erythromycin and is not related to the penicillin class.


Q: Are there any limitations on driving while taking Clariget?

A: Official sources advise caution because Clariget may cause central nervous system side effects such as dizziness, confusion, or disorientation. Regulatory sources recommend caution regarding driving or operating heavy machinery until an individual is aware of how the medicine affects them.


Q: What does official guidance say about Clariget use during pregnancy?

A: Official guidance generally does not recommend use during pregnancy unless there are no alternative treatments and the potential benefit is judged by a physician to outweigh the potential risk to the fetus. Studies in animals have shown evidence of fetal harm, and human data is limited, especially during the first trimester.


Q: Is it possible to become resistant to the effects of Clariget?

A: Yes. Regulatory guidance warns that taking the antibiotic incorrectly can lead to resistance. Specifically, skipping doses or stopping Clariget too soon may result in the infection not being completely treated and the remaining bacteria potentially becoming resistant to the antibiotic.


Q: Is Clariget a sulfa drug?

A: No. Clariget is the trade name for the macrolide antibiotic clarithromycin. It does not contain any sulfa (sulfonamide) ingredients, which are part of a different class of medications.


Q: Can Clariget be taken for a tooth infection?

A: Official indications cover the treatment of susceptible bacterial infections of various types. While not explicitly naming 'tooth infection,' clarithromycin is a recognized antibiotic and may be prescribed by a physician or dentist for bacterial infections that affect the mouth and gums.


Q: Does Clariget affect blood sugar levels?

A: Official drug interaction information notes that using clarithromycin together with insulin and certain diabetes medications has occasionally resulted in hypoglycemia (low blood sugar). Patients with diabetes are typically advised to monitor their blood sugar closely if taking this medicine.


Q: What happens if I accidentally take too much Clariget?

A: If an accidental overdose occurs, immediate medical attention is required. Regulatory sources report that common symptoms of overdose typically include stomach pain, nausea, vomiting, and diarrhea.


Q: Does Clariget require a prescription?

A: Yes. Clariget (clarithromycin) is classified as a Prescription-Only Medicine (POM) in all official regulatory documentation and cannot be obtained without a valid prescription from a licensed healthcare professional.


Q: Why do some people use Clariget for ear infections?

A: Regulatory bodies have approved clarithromycin for the treatment of certain bacterial infections of the ears (specifically acute otitis media or middle ear infection) in certain populations. It is effective against the specific organisms that commonly cause these types of infections.


Q: Is Clariget prescribed for sinus infections?

A: Yes. Regulatory indications include the treatment of certain bacterial infections of the sinuses (specifically acute maxillary sinusitis). Clarithromycin is recognized as an effective treatment against the susceptible bacteria that cause these infections.


Q: Can Clariget affect my sleep?

A: Yes. Official product information documents list insomnia (difficulty sleeping) as a common adverse reaction and somnolence (drowsiness) as an uncommon adverse reaction. Patients may observe an impact on their ability to sleep.


Q: What are the restrictions on Clariget use for people with myasthenia gravis?

A: Official guidance advises that caution should be used when Clariget is administered to patients with the muscle-weakening condition known as Myasthenia Gravis (MG). The medicine is noted in regulatory documents to have the potential to make the symptoms of MG worse.

How should Clariget be stored and disposed of?

Clariget (Clarithromycin) must be stored according to specific, documented regulatory requirements to maintain its stability.

Storage and Stability Conditions

Formulation Required Storage Temperature Stability Constraint
Tablets Controlled room temperature (20 C to 25 C) Protect from light and excessive moisture.
Oral Suspension (Reconstituted) Between 15 C and 30 C Must not be refrigerated or frozen; discard after 14 days.

The medicine must be kept in the container it came in, with the container tightly closed. All clarithromycin products must be stored out of the reach of children.

Disposal

Throw away unused or expired Clariget. Disposal must be performed in accordance with local requirements for pharmaceutical waste. The product should generally not be flushed down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clariget found in:

A-Z Index: